Clinical trial · Interventional
The Clinical Trial About Treatment of Benign Uterus Myoma by Haifu Focused Ultrasound Tumor Therapeutic System
The Clinical Trial About Treatment of Benign Uterus Myoma by Haifu Focused Ultrasound Tumor Therapeutic System.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Uterine benign tumor including myoma is the most common female benign pelvic tumor. Magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU) has been considered to be a minimal invasive treatment. The device used in this trial will be Haifu Focused Ultrasound tumor therapeutic System. In this trial, the investigators will observe the possibility of complication and tumor response of treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Benign Uterine Tumor | Benign Uterine Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Haifu Focused Ultrasound tumor therapeutic System | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Haifu Focused Ultrasound tumor therapeutic System
- interventionNames
- Device: Haifu Focused Ultrasound tumor therapeutic System
Primary outcomes (1)
- measure
- Evaluation of tumour response
- timeFrame
- 3 month after treatment
- description
- Evaluation of tumour response according to the modified RECIST criteria by sequencing MR imaging
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: 1. Benign uterine fibroids. 2. Women over the age of 20. 3. Abdominal circumference \<100 cm. 4. The largest fibroids are ≥ 4 cm. Exclusion Criteria: 1. Pregnant women or those with positive pregnancy test results. 2. Those with other pelvic diseases. 3. Those with immune diseases. 4. There are unsuitable interfaces in the ultrasonic treatment path. 5. Those with tumor calcification. 6. People with severe heart, blood vessel and kidney disease. 7. Those with abnormal coagulation function and low platelets. 8. Type III fibroids according to Funaki classification
References
Publications (0)
Data not yet available